These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15379778)

  • 21. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
    Dalaker M; Bonesrønning JH
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A rare case of non-Hodgkins B-cell lymphoma in a psoriatic patient: a case report and literature review.
    Gattu S; Becker EM; Koo JY
    J Drugs Dermatol; 2010 Oct; 9(10):1277-81. PubMed ID: 20941955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective analysis of combination methotrexate-cyclosporine therapy in moderate-severe psoriasis.
    Mohanan S; Ramassamy S; Chandrashekar L; Thappa DM
    J Dermatolog Treat; 2014 Feb; 25(1):50-3. PubMed ID: 23469768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psoriasis: what is new in nonbiologic systemic therapy in the era of biologics?
    Kanwar AJ; Yadav S; Dogra S
    Indian J Dermatol Venereol Leprol; 2010; 76(6):622-33. PubMed ID: 21079305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
    Tzu J; Kerdel F
    Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining the new biologic agents with our current psoriasis armamentarium.
    Lebwohl M
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S118-24. PubMed ID: 12894135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use.
    Behnam SM; Behnam SE; Koo JY
    J Drugs Dermatol; 2005; 4(2):189-94. PubMed ID: 15776776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of severe psoriasis.
    Puig L
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():17-8. PubMed ID: 22758913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.
    Gisondi P; Cazzaniga S; Chimenti S; Giannetti A; Maccarone M; Picardo M; Girolomoni G; Naldi L;
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e30-41. PubMed ID: 22313340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.
    Yamauchi PS; Lowe NJ
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S135-8. PubMed ID: 16488328
    [No Abstract]   [Full Text] [Related]  

  • 31. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate treatment in 13 children with severe plaque psoriasis.
    Collin B; Vani A; Ogboli M; Moss C
    Clin Exp Dermatol; 2009 Apr; 34(3):295-8. PubMed ID: 19175782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse events from systemic therapies for psoriasis are common in clinical practice.
    Pearce DJ; Higgins KB; Stealey KH; Balkrishnan R; Crane MM; Camacho F; Fleischer AB; Feldman SR
    J Dermatolog Treat; 2006; 17(5):288-93. PubMed ID: 17092859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moderate to severe plaque psoriasis - treatment with drugs of the classic scheme.
    Arnone M; Carvalho AVE; Takahashí MDF; Bernardo WM
    Rev Assoc Med Bras (1992); 2019 May; 65(4):530-534. PubMed ID: 31066805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
    Kalb RE; Gurske J
    J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From laboratory to clinic: rationale for biologic therapy.
    Mehlis S; Gordon KB
    Dermatol Clin; 2004 Oct; 22(4):371-7, vii-viii. PubMed ID: 15450333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of biologicals in psoriasis].
    Friedrich M; Philipp S; Sabat R; Asadullah K; Sterry W
    Z Rheumatol; 2003 Oct; 62(5):439-49. PubMed ID: 14579031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab-induced remission of extensive plaque psoriasis.
    Amital H; Ingber A; Rubinow A
    Isr Med Assoc J; 2003 Nov; 5(11):827-8. PubMed ID: 14650114
    [No Abstract]   [Full Text] [Related]  

  • 39. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India.
    Kaur I; Dogra S; De D; Kanwar AJ
    Pediatr Dermatol; 2008; 25(2):184-8. PubMed ID: 18429775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excessive drowsiness with low-dose methotrexate.
    Handa S; Saraswat A; Kaur I; Kumar B
    Int J Dermatol; 2004 Sep; 43(9):701-2. PubMed ID: 15357759
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.